Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue: 2017-2025

Historic Non-Current Deffered Revenue for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $4.1 million.

  • Crinetics Pharmaceuticals' Non-Current Deffered Revenue fell 20.89% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 20.89%. This contributed to the annual value of $4.7 million for FY2024, which is 0.97% down from last year.
  • Crinetics Pharmaceuticals' Non-Current Deffered Revenue amounted to $4.1 million in Q3 2025, which was up 2.96% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Non-Current Deffered Revenue peaked at $7.2 million during Q1 2022, and registered a low of $2,000 during Q4 2021.
  • Its 3-year average for Non-Current Deffered Revenue is $4.7 million, with a median of $4.7 million in 2024.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Non-Current Deffered Revenue slumped by 91.30% in 2021 and then soared by 304,950.00% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $2,000 in 2021, then spiked by 304,950.00% to $6.1 million in 2022, then fell by 22.14% to $4.8 million in 2023, then declined by 0.97% to $4.7 million in 2024, then dropped by 20.89% to $4.1 million in 2025.
  • Its Non-Current Deffered Revenue stands at $4.1 million for Q3 2025, versus $4.0 million for Q2 2025 and $4.3 million for Q1 2025.